Danish small molecule lead discovery company Nuevolution says Professor Paul Workman has joined the company as Scientific Advisor. Workman brings extensive knowledge and expertise within the oncology field to Nuevolution as well as deep understanding of bringing research discoveries to commercial launch.
Professor Workman has achieved a high level of success in academia, biotech companies and the pharmaceutical industry. He is a Biochemist and Cancer Pharmacologist by training and he has worked at a number of academic institutions including Cambridge University, UK, Stanford University, California and the University of Glasgow, UK before moving to AstraZeneca, Alderley Park, UK as Head of the Cancer Bioscience Section in 1993.
In 1997, he joined The Institute of Cancer Research (ICR), London to build the Cancer Research UK Cancer Therapeutics Unit (CTU) and also co-founded two biotech companies, Piramed Pharma and Chroma Therapeutics.
As well as being the Director of the ICR’s CTU and Harrap Professor of Pharmacology and Therapeutics, Workman was recently appointed Interim Chief Executive of ICR, having been Deputy CEO for the last three years. He has received many scientific achievement awards including the American Association of Cancer Research Team Science Award (Team Leader) in 2012 and Cancer Research UK Translational Cancer Research Prize (Joint Leader of HSP90 Team) in 2013. In addition, he has received both the Sosnovsky Award in Cancer Therapy (2010) and the World Entrepreneur of the Year Award (2012) from the Royal Society of Chemistry and earlier this year received the international Raymond Bourgine Award for excellence in cancer research.
